Arvinas and Pfizer Advance Third-Party Commercialization Strategy for Breast Cancer ER Degrader Vepdegestrant

Intelligent Finance APP learned that Arvinas (ARVN.US), a new force in the U.S. biotechnology industry, and its partner, pharmaceutical giant Pfizer (PFE.US), have decided to out-license the commercial rights of the significant innovative drug vepdegestrant — meaning they will sublicense the drug's commercial rights. Vepdegestrant is an investigational estrogen receptor protein degrader (breast cancer ER degrader) for breast cancer treatment. Its application for approval was submitted to the U.S. Food and Drug Administration (FDA) in June.

According to reports, Arvinas stated in a press release that the commercialization initiative authorized to a third party "is the best path forward to unlock the full value of vepdegestrant and ensure timely market availability if regulatory approval is granted."

Arvinas and Pfizer jointly stated that they have decided to grant a third party (licensee) the rights to develop, manufacture, market/commercialize their products, technologies, or intellectual property. The licensee will advance these rights and make agreed-upon payments, including upfront fees, milestone payments, and royalties. This approach is particularly common in the global pharmaceutical industry, such as licensing the commercial rights of a drug in a specific region or globally.

Arvinas stated that, in view of the significant changes to the vepdegestrant program, the company will cut 15% of its workforce, seek greater strategic business development opportunities, and identify more areas for efficiency improvement.

It is reported that the company has three important candidate drugs in Phase I clinical stage: ARV-102 (mainly for progressive supranuclear palsy and Parkinson's disease); ARV-393 (for non-Hodgkin's lymphoma); and ARV-806 (for solid tumor malignancies).

What is the new biotech force Arvinas? What is the hype about vepdegestrant?

Headquartered in the United States, Arvinas (NASDAQ: ARVN), a clinical-stage biotechnology company, focuses on Targeted Protein Degradation (TPD) as its core technology. Utilizing its proprietary PROTAC platform, Arvinas develops "novel categories" of drugs and advances pipelines in areas such as oncology based on the PROTAC (Proteolysis-Targeting Chimeras) platform, while engaging in external collaborations for development and commercialization — for instance, collaborating with Pfizer on breast cancer projects. Vepdegestrant, an innovative drug jointly developed with the U.S. pharmaceutical giant Pfizer, represents Arvinas' flagship innovative drug project and primary value driver.

Vepdegestrant (ARV-471) is an orally administered PROTAC estrogen receptor (ER) degrader, used for ER+/HER2- locally advanced or metastatic breast cancer; one end of the molecule binds to ER, while the other end recruits and binds to E3 ubiquitin ligase (such as cereblon), inducing ER ubiquitination and subsequent proteasomal degradation.

The latest data shows that vepdegestrant has received FDA Fast Track designation; the 2025 NDA (New Drug Application) has been submitted and accepted by the FDA, and was accepted for review by the FDA in August — it is Arvinas' project closest to market entry and is currently still in the review stage; Arvinas/Pfizer has decided to out-license its commercial rights. Vepdegestrant is an oral PROTAC (targeted protein degradation) estrogen receptor degrader that tags ER for degradation via E3 ligase and subsequent proteasomal clearance, fundamentally different from traditional SERDs/antagonists which "only block the receptor," representing a breakthrough innovative drug class.